SecBot SecBot
8-K ·Filed Oct 30, 2026

RGEN

REPLIGEN CORP
NEUTRAL
Impact 5/10
Horizondays Processed2d 16h ago SEC0001628280-26-068382
8-K context-dependent: Items 3.02, 8.01
Actionable Insight • Neutral

Monitor the closing of the transaction on November 6, 2026, and any subsequent share repurchase activity. The reduced interest expense and extended maturity profile are credit-positive, but the potential dilution from conversion (up to 5.3 million shares) and the use of cash for share repurchases rather than organic investment should be weighed against any future M&A announcements.

DirectionNeutral
Confidencehigh
Horizondays

Price Chart

Loading chart...

Executive Summary

Repligen entered into privately negotiated exchange and subscription agreements to issue $1.0 billion aggregate principal amount of 0.25% Convertible Senior Notes due 2031. Approximately $541.4 million of the new notes will be exchanged for $456.8 million of existing 1.00% 2028 notes, and approximately $458.6 million will be issued for cash. The company will use $120 million of the cash proceeds to repurchase shares at $188.64 per share to facilitate the transaction, with the remainder for working capital and potential acquisitions. The transaction extends debt maturity, reduces interest expense, and is expected to be nominally accretive to adjusted EPS in 2026.

Key Financial Metrics

Offering Size
$1.0B

Key Facts

  • Issued $1.0 billion aggregate principal amount of 0.25% Convertible Senior Notes due 2031
  • $541.4 million of new notes exchanged for $456.8 million of existing 1.00% 2028 notes
  • $458.6 million of new notes issued for cash, with gross proceeds of approximately $458.6 million
  • Initial conversion price of approximately $226.37 per share, a 20% premium over the October 29, 2026 closing price of $188.64
  • Approximately $143.2 million of 2028 notes will remain outstanding after the transaction
  • Company will repurchase $120 million of its common stock at $188.64 per share from certain purchasers
  • Placement agent intends to purchase approximately $30 million of common stock from certain participants at a discount
  • Up to 5,301,100 shares may be issued upon conversion of the new notes
  • Transaction expected to close on or about November 6, 2026

Financial Impact

Gross cash proceeds of approximately $458.6 million; $120 million used for share repurchase; remaining for working capital and M&A. Interest expense reduced from 1.00% to 0.25% on the exchanged and newly issued notes.

debtinterest expensedilutioncash

Risk Factors

  • Potential dilution from conversion of up to 5,301,100 shares of common stock
  • Concurrent share repurchases and placement agent purchases may affect market price
  • Use of proceeds for acquisitions carries integration risk
  • Approximately $143.2 million of 2028 notes remain outstanding with original terms

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
85% bullish (27 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-068382
Document: 0001628280-26-068382-index.html0001628280-26-068382
Document: 0001628280-26-068382.txt0001628280-26-068382
15 reports for RGEN
Performance horizon
100% Hit rate @ T+60 4 of 4 directional calls Went positive at some point 8 of 8 best @ T+60▲ +31.47%Jul 22, 2026
Filters
Rows
Reports for RGEN, sortable and filterable
TypeNow
Oct 30, 2026
2d ago
8-K
NEUTRAL ★ 5/10
$188.42awaiting T+60awaiting T+60$176.94 (−6.09%)
Oct 27, 2026
5d ago
8-K
BULLISH ★ 6/10
No priceawaiting T+60awaiting T+60No price
Oct 27, 2026
5d ago
Press Release
BULLISH ★ 6/10
$175.80awaiting T+60awaiting T+60$176.94 (+0.65%)
Oct 15, 2026
17d ago
Institutional Cluster
MIXED ★ 3/10
$184.17awaiting T+60awaiting T+60$176.94 (−3.93%)
Oct 7, 2026
25d ago
SC 13G/A
BULLISH ★ 5/10
$167.22awaiting T+60awaiting T+60$176.94 (+5.81%)
Oct 6, 2026
26d ago
8-K
BULLISH ★ 6/10
$174.86awaiting T+60awaiting T+60$176.94 (+1.19%)
Oct 6, 2026
26d ago
Press Release
BULLISH ★ 6/10
$174.86awaiting T+60awaiting T+60$176.94 (+1.19%)
Aug 24, 2026
9w ago
S-4
NEUTRAL ★ 6/10
$181.69awaiting T+60awaiting T+60$176.94 (−2.61%)
Jul 28, 2026
13w ago
8-K
BULLISH ★ 7/10
$145.34 $180.01▲ +23.85%▲ +19.50%$176.94 (+21.74%)
Jul 22, 2026
14w ago
425 / 8-K
BULLISH ★ 7/10
$140.09 $184.17▲ +31.47%▲ +28.20%$176.94 (+26.30%)
Showing 10 of 15

US Market Status

Market Closed · Opens Tue (11h 39m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 30, 2026